Beasley, Allen, Crow, Methvin, Portis & Miles, P.C.

An electrical stimulation device to speed up the digestion in overweight patients with type 2 diabetes is showing promising results in the improvement of glycemic control, according to Med Page Today. The device works by discharging electrical current into the gastric antrum. It was originally developed as a nonpharmacologic alternative for treatment of gastroparesis, which is often treated with the medication Reglan (metoclopramide).

Some patients with gastroparesis don’t respond to treatment and some may experience severe adverse events from the medication. For example, Reglan recently fell under a black box warning after reports of a serious movement disorder called Tardive Dyskinesia in some patients who took the medication. Given the risks of medication, alternative therapies like the stimulation device seem more attractive. 

Read the rest of this entry »

The Food and Drug Administration (FDA) has approved the safety labeling changes of the heartburn and gastroparesis medication Reglan (metoclopramide) which includes a black box warning of a serious and often irreversible movement disorder called Tardive Dyskinesia. The warning includes Reglan (metoclopramide) tablets, ODT (orally disintegrating tablets), and injection.

Read the rest of this entry »